To the full analysis
Buyback calculator for Kuros Biosciences
Kuros Biosciences stock: key metrics
KURN.SWKuros Biosciences had an operating margin of 6% and a return on invested capital (ROIC) of 7.5% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | −1,447.0% | −4,846.8% | −4,772.4% |
| 2007 | 51.5% | −23.1% | −19.2% |
| 2008 | 100.0% | −121.1% | −131.9% |
| 2009 | 100.0% | −299.1% | −272.6% |
| 2010 | 100.0% | −17.3% | −6.5% |
| 2011 | 100.0% | −1,254.9% | −1,195.4% |
| 2012 | 100.0% | −1,226.8% | −837.8% |
| 2013 | −1,194.9% | −2,326.6% | −3,082.6% |
| 2014 | −910.1% | −1,893.7% | −3,402.6% |
| 2015 | 91.1% | 10.3% | 98.0% |
| 2016 | −645.4% | −2,011.9% | −1,860.9% |
| 2017 | −518.9% | −3,041.8% | −3,086.9% |
| 2018 | −377.8% | −1,919.9% | −1,635.4% |
| 2019 | −3.1% | −444.8% | −439.4% |
| 2020 | 41.4% | −289.2% | −285.2% |
| 2021 | 72.9% | −63.5% | −54.6% |
| 2022 | 59.9% | −74.8% | −81.1% |
| 2023 | 71.3% | −39.3% | no data |
| 2024 | 82.1% | −6.6% | −4.9% |
| 2025 | 86.4% | 6.0% | 1.7% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −75.3% | −56.6% | −60.2% |
| 2007 | −12.6% | −8.0% | −5.6% |
| 2008 | −81.6% | −17.8% | −23.5% |
| 2009 | −100.0% | −26.9% | −36.1% |
| 2010 | −22.0% | −5.4% | −2.7% |
| 2011 | 160.8% | −40.7% | −60.9% |
| 2012 | −91.9% | −39.6% | −30.3% |
| 2013 | −100.0% | −59.7% | −76.1% |
| 2014 | 129.8% | −65.0% | −100.0% |
| 2015 | 200.0% | 7.9% | 191.1% |
| 2016 | −51.5% | −73.7% | −45.1% |
| 2017 | −22.5% | −31.1% | −19.1% |
| 2018 | −15.3% | −18.9% | −13.6% |
| 2019 | −14.5% | −15.3% | −12.8% |
| 2020 | −13.6% | −15.6% | −12.2% |
| 2021 | −9.8% | −12.0% | −8.3% |
| 2022 | −21.2% | −20.4% | −17.6% |
| 2023 | no data | −22.8% | no data |
| 2024 | −6.3% | −9.0% | −4.4% |
| 2025 | 3.2% | 7.5% | 2.0% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CHF 0.8331)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 12 Dec 2025)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.